261 related articles for article (PubMed ID: 21081644)
1. Progesterone receptor membrane component 1 inhibits the activity of drug-metabolizing cytochromes P450 and binds to cytochrome P450 reductase.
Szczesna-Skorupa E; Kemper B
Mol Pharmacol; 2011 Mar; 79(3):340-50. PubMed ID: 21081644
[TBL] [Abstract][Full Text] [Related]
2. Progesterone receptor membrane component 1 modulates human cytochrome p450 activities in an isoform-dependent manner.
Oda S; Nakajima M; Toyoda Y; Fukami T; Yokoi T
Drug Metab Dispos; 2011 Nov; 39(11):2057-65. PubMed ID: 21825115
[TBL] [Abstract][Full Text] [Related]
3. Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes.
Hughes AL; Powell DW; Bard M; Eckstein J; Barbuch R; Link AJ; Espenshade PJ
Cell Metab; 2007 Feb; 5(2):143-9. PubMed ID: 17276356
[TBL] [Abstract][Full Text] [Related]
4. Progesterone receptor membrane component 1 (PGRMC1) binds and stabilizes cytochromes P450 through a heme-independent mechanism.
McGuire MR; Mukhopadhyay D; Myers SL; Mosher EP; Brookheart RT; Kammers K; Sehgal A; Selen ES; Wolfgang MJ; Bumpus NN; Espenshade PJ
J Biol Chem; 2021 Nov; 297(5):101316. PubMed ID: 34678314
[TBL] [Abstract][Full Text] [Related]
5. Reconstitution of the enzymatic activities of cytochrome P450s using recombinant flavocytochromes containing rat cytochrome b(5) fused to NADPH--cytochrome P450 reductase with various membrane-binding segments.
Gilep AA; Guryev OL; Usanov SA; Estabrook RW
Arch Biochem Biophys; 2001 Jun; 390(2):215-21. PubMed ID: 11396924
[TBL] [Abstract][Full Text] [Related]
6. S2R(Pgrmc1): the cytochrome-related sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling.
Ahmed IS; Chamberlain C; Craven RJ
Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):361-70. PubMed ID: 22292588
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Interactions Among CYP1A2, CYP2B4, and NADPH-cytochrome P450 Reductase: Identification of Specific Protein Complexes.
Connick JP; Reed JR; Backes WL
Drug Metab Dispos; 2018 Mar; 46(3):197-203. PubMed ID: 29233819
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome
Kim D; Kim V; Tateishi Y; Guengerich FP
Drug Metab Dispos; 2021 Oct; 49(10):902-909. PubMed ID: 34330716
[TBL] [Abstract][Full Text] [Related]
9. Reaction of human cytochrome P450 3A4 with peroxynitrite: nitrotyrosine formation on the proximal side impairs its interaction with NADPH-cytochrome P450 reductase.
Lin HL; Kenaan C; Zhang H; Hollenberg PF
Chem Res Toxicol; 2012 Dec; 25(12):2642-53. PubMed ID: 23016756
[TBL] [Abstract][Full Text] [Related]
10. Comparison of CYP3A4 and CYP3A5: the effects of cytochrome b5 and NADPH-cytochrome P450 reductase on testosterone hydroxylation activities.
Lee SJ; Goldstein JA
Drug Metab Pharmacokinet; 2012; 27(6):663-7. PubMed ID: 22785258
[TBL] [Abstract][Full Text] [Related]
11. Liver microsomal lipid enhances the activity and redox coupling of colocalized cytochrome P450 reductase-cytochrome P450 3A4 in nanodiscs.
Liu KC; Hughes JMX; Hay S; Scrutton NS
FEBS J; 2017 Jul; 284(14):2302-2319. PubMed ID: 28618157
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition compromises direct retention of cytochrome P450 2C2 in the endoplasmic reticulum.
Szczesna-Skorupa E; Kemper B
Exp Cell Res; 2008 Oct; 314(17):3221-31. PubMed ID: 18755184
[TBL] [Abstract][Full Text] [Related]
13. In vitro inhibition of SKOV-3 cell migration as a distinctive feature of progesterone receptor membrane component type 2 versus type 1.
Albrecht C; Huck V; Wehling M; Wendler A
Steroids; 2012 Dec; 77(14):1543-50. PubMed ID: 23064006
[TBL] [Abstract][Full Text] [Related]
14. An enzymatically active chimeric protein containing the hydrophilic form of NADPH-cytochrome P450 reductase fused to the membrane-binding domain of cytochrome b5.
Gilep AA; Guryev OL; Usanov SA; Estabrook RW
Biochem Biophys Res Commun; 2001 Jun; 284(4):937-41. PubMed ID: 11409883
[TBL] [Abstract][Full Text] [Related]
15. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli.
Yamazaki H; Nakamura M; Komatsu T; Ohyama K; Hatanaka N; Asahi S; Shimada N; Guengerich FP; Shimada T; Nakajima M; Yokoi T
Protein Expr Purif; 2002 Apr; 24(3):329-37. PubMed ID: 11922748
[TBL] [Abstract][Full Text] [Related]
16. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
17. Effect of 17-alpha-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites.
Kent UM; Mills DE; Rajnarayanan RV; Alworth WL; Hollenberg PF
J Pharmacol Exp Ther; 2002 Feb; 300(2):549-58. PubMed ID: 11805216
[TBL] [Abstract][Full Text] [Related]
18. PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding.
Rohe HJ; Ahmed IS; Twist KE; Craven RJ
Pharmacol Ther; 2009 Jan; 121(1):14-9. PubMed ID: 18992768
[TBL] [Abstract][Full Text] [Related]
19. In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition.
Gallemann D; Wimmer E; Höfer CC; Freisleben A; Fluck M; Ladstetter B; Dolgos H
Drug Metab Dispos; 2010 Jun; 38(6):905-16. PubMed ID: 20219851
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy.
Lengler J; Omann M; Düvier D; Holzmüller H; Gregor W; Salmons B; Günzburg WH; Renner M
Biochem Pharmacol; 2006 Sep; 72(7):893-901. PubMed ID: 16887103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
